Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma

被引:18
作者
Zhang, Bo [1 ,2 ]
Zhao, Jilong [1 ,2 ]
Liu, Bing [1 ,2 ]
Shang, Yanan [1 ,2 ]
Chen, Fei [1 ,2 ]
Zhang, Sidi [1 ,2 ]
He, Jiayao [1 ,3 ]
Fan, Yumei [1 ,2 ]
Tan, Ke [1 ,2 ]
机构
[1] Hebei Normal Univ, Coll Life Sci, Key Lab Mol & Cellular Biol, Minist Educ, Shijiazhuang, Peoples R China
[2] Hebei Normal Univ, Coll Life Sci, Key Lab Anim Physiol Biochem & Mol Biol Hebei Prov, Shijiazhuang, Peoples R China
[3] Hebei Med Univ, Handan Cent Hosp, Dept Neurosurg, Shijiazhuang, Peoples R China
关键词
ferroptosis; hepatocellular carcinoma; prognosis; FRG signature; immune infiltration; CELL-DEATH; SORAFENIB RESISTANCE; CANCER; BIOMARKER; METABOLISM; RESPONSES; PROTECTS; SLC1A5;
D O I
10.3389/fmolb.2022.940575
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma (HCC) is a cancer that is sensitive to ferroptosis, and immunotherapy has emerged as a promising treatment for HCC patients. However, the prognostic potential of ferroptosis-related genes (FRGs) and the effect of ferroptosis on the tumor immune microenvironment in HCC remain largely obscure. Here, we analyzed the expression pattern of FRGs using the TCGA, ICGC and GEO databases. The expression of most FRGs was upregulated in HCC tissues compared with normal liver tissues. Three independent clusters were determined by consensus clustering analysis based on FRG expression in HCC. Cluster 3 exhibited higher expression, unfavorable prognosis, and higher histological tumor stage and grade than clusters 1 and 2. CIBERSORT analysis indicated different infiltrating levels of various immune cells among the three clusters. Moreover, most immune checkpoint genes were highly expressed in cluster 3. Univariate Cox regression and LASSO regression analyses were performed to develop a five FRG-based prognostic risk model using the TCGA and ICGC datasets. Kaplan-Meier analysis and ROC curves were performed to verify the prognostic potential of the risk model. A nomogram containing independent prognostic factors was further developed. Compared with low-risk patients, high-risk HCC patients exhibited worse overall survival (OS). In addition, this risk model was significantly correlated with the infiltrating levels of six major types of immune cells in HCC. Finally, the relationships between the five FRGs and drug sensitivity were investigated. The present study suggests that the five FRGs could elucidate the molecular mechanisms of HCC and lead to a new direction for the improvement of predictive, preventive, and personalized medicine for HCC.
引用
收藏
页数:22
相关论文
共 43 条
  • [1] Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
    Angeli, Jose Pedro Friedmann
    Krysko, Dmitri, V
    Conrad, Marcus
    [J]. NATURE REVIEWS CANCER, 2019, 19 (07) : 405 - 414
  • [2] Ferroptosis in Cancer Cell Biology
    Bebber, Christina M.
    Mueller, Fabienne
    Clemente, Laura Prieto
    Weber, Josephine
    von Karstedt, Silvia
    [J]. CANCERS, 2020, 12 (01)
  • [3] Chen F, 2021, AGING-US, V13, P21671, DOI 10.18632/aging.203512
  • [4] The multifaceted role of ferroptosis in liver disease
    Chen, Junyi
    Li, Xiaopeng
    Ge, Chaodong
    Min, Junxia
    Wang, Fudi
    [J]. CELL DEATH AND DIFFERENTIATION, 2022, 29 (03) : 467 - 480
  • [5] Broadening horizons: the role of ferroptosis in cancer
    Chen, Xin
    Kang, Rui
    Kroemer, Guido
    Tang, Daolin
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (05) : 280 - 296
  • [6] CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma
    Chen, Yiran
    Li, Li
    Lan, Jie
    Cui, Yang
    Rao, Xiaosong
    Zhao, Jing
    Xing, Tao
    Ju, Gaoda
    Song, Guangtao
    Lou, Jizhong
    Liang, Jun
    [J]. MOLECULAR CANCER, 2022, 21 (01)
  • [7] Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
    Dixon, Scott J.
    Lemberg, Kathryn M.
    Lamprecht, Michael R.
    Skouta, Rachid
    Zaitsev, Eleina M.
    Gleason, Caroline E.
    Patel, Darpan N.
    Bauer, Andras J.
    Cantley, Alexandra M.
    Yang, Wan Seok
    Morrison, Barclay, III
    Stockwell, Brent R.
    [J]. CELL, 2012, 149 (05) : 1060 - 1072
  • [8] Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]
  • [9] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H., III
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    dela Cruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    Dastani, Homa B.
    Melero, Ignacio
    [J]. LANCET, 2017, 389 (10088) : 2492 - 2502
  • [10] Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration
    Fan, Yumei
    Liu, Bing
    Chen, Fei
    Song, Zhiyuan
    Han, Bihui
    Meng, Yanxiu
    Hou, Jiajie
    Cao, Pengxiu
    Chang, Yanzhong
    Tan, Ke
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12